CalciMedica (NASDAQ:CALC) Upgraded at Wall Street Zen
by Tristan Rich · The Markets DailyWall Street Zen upgraded shares of CalciMedica (NASDAQ:CALC – Free Report) to a sell rating in a research report released on Saturday morning.
Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of CalciMedica in a report on Wednesday, October 8th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, CalciMedica currently has a consensus rating of “Hold” and a consensus target price of $16.00.
Get Our Latest Stock Report on CalciMedica
CalciMedica Trading Down 2.8%
Shares of CALC opened at $5.13 on Friday. CalciMedica has a 1 year low of $1.42 and a 1 year high of $7.20. The company has a current ratio of 4.03, a quick ratio of 4.04 and a debt-to-equity ratio of 1.39. The stock has a 50 day simple moving average of $4.88 and a 200-day simple moving average of $3.65. The stock has a market cap of $73.92 million, a PE ratio of -3.17 and a beta of 0.49.
CalciMedica (NASDAQ:CALC – Get Free Report) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.02. On average, sell-side analysts predict that CalciMedica will post -2.21 EPS for the current fiscal year.
Institutional Investors Weigh In On CalciMedica
Institutional investors and hedge funds have recently made changes to their positions in the company. Stonehage Fleming Financial Services Holdings Ltd acquired a new position in shares of CalciMedica during the third quarter valued at $165,000. Sheets Smith Investment Management acquired a new position in CalciMedica during the 3rd quarter valued at about $157,000. Envestnet Asset Management Inc. lifted its position in CalciMedica by 58.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock valued at $149,000 after purchasing an additional 34,386 shares during the period. 180 Wealth Advisors LLC boosted its stake in shares of CalciMedica by 207.6% in the 2nd quarter. 180 Wealth Advisors LLC now owns 50,450 shares of the company’s stock valued at $81,000 after purchasing an additional 34,050 shares during the last quarter. Finally, Sound View Wealth Advisors Group LLC acquired a new stake in shares of CalciMedica during the 2nd quarter worth approximately $32,000.
About CalciMedica
CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.
The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.